Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbonic anhydrase 9 (CA9, also known as CA-IX or G250) is a transmembrane zinc metalloenzyme that catalyzes the reversible hydration of carbon dioxide into bicarbonate and protons. It is highly overexpressed in many solid tumors, particularly clear cell renal cell carcinoma (ccRCC), under the control of hypoxia-inducible factor 1-alpha (HIF-1α) in response to tumor hypoxia. In contrast, its expression in normal tissues is highly restricted, primarily confined to the gastrointestinal tract. CA9 plays a critical role in tumor pH regulation, driving extracellular acidification and maintaining a neutral intracellular pH, which promotes cancer cell survival, invasion, metastasis, and resistance to chemotherapy and radiation. Because of its tumor-specific expression and cell-surface localization, CA9 is a highly attractive therapeutic and diagnostic target. Therapeutic strategies include small-molecule inhibitors (such as SLC-0111) that block its catalytic activity, monoclonal antibodies (such as girentuximab) that trigger antibody-dependent cellular cytotoxicity, and radiolabeled conjugates (such as 89Zr-DFO-girentuximab and 177Lu-girentuximab) for non-invasive PET imaging and targeted radionuclide therapy.
Carbonic anhydrase inhibition, targeted radiopharmaceutical imaging, targeted radionuclide therapy, and antibody-dependent cellular cytotoxicity (ADCC).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbonic anhydrase 9 (CA9).